Hydrogen Gas Inhalation Treatment in Acute Cerebral Infarction: A Randomized Controlled Clinical Study on Safety and Neuroprotection.
Hirohisa Ono, Yoji Nishijima, Shigeo Ohta, Masaki Sakamoto, Kazunori Kinone, Tohru Horikosi, Mituyuki Tamaki, Hirosi Takeshita, Tomoko Futatuki, Wataru Ohishi, Taichi Ishiguro, Saori Okamoto, Shou Ishii, Hiroko Takanami · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2017
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 50 patients with a therapeutic time window of 6 to 24 hours, the H₂ group showed no significant adverse effects with improvements in oxygen saturation. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 50 patients with a therapeutic time window of 6 to 24 hours. The H₂ group showed no significant adverse effects with improvements in oxygen saturation.
What the Researchers Studied
The researchers studied 50 patients with a therapeutic time window of 6 to 24 hours. The study used a randomized human clinical trial. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
4% inhaled H₂ concentration. The H₂ group showed no significant adverse effects with improvements in oxygen saturation. The authors concluded that H₂ treatment was safe and effective in patients with acute cerebral infarction.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 50 patients with a therapeutic time window of 6 to 24 hours. The reported sample size was 50. The study used a randomized human clinical trial. The hydrogen delivery method was inhaled hydrogen gas. The reported hydrogen concentration was 4% inhaled H₂ concentration.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.